||||||||||ALG-093702 / Aligos Therap Preclinical pharmacokinetic, pharmacodynamic and efficacy relationships of ALG-093702, a liver targeted PD-L1 small molecule inhibitor, in different in vivo models (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_1726; We discovered a liver-targeted PD-L1 small molecule inhibitor, ALG-093702, with similar in vitro potency and in vivo PD-L1 target occupancy and tumor growth inhibition as the PD-L1 antibody drug, durvalumab. The preclinical PK/PD/efficacy correlation provides guidance for the efficacious human dose prediction and dosing strategy for clinical studies of oral liver targeted PD-L1 small molecule inhibitor.